Autoantibodies against aldehyde-modified collagen type IV are associated with risk of development of myocardial infarction.

about

Autoantibodies against aldehyde-modified collagen type IV are associated with risk of development of myocardial infarction.

Item

http://www.wikidata.org/entity/Q47750132

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Autoantibodies against aldehyd ...... ment of myocardial infarction.

@en

Autoantibodies against aldehyd ...... ment of myocardial infarction.

@nl

type

Item

label

Autoantibodies against aldehyd ...... ment of myocardial infarction.

@en

Autoantibodies against aldehyd ...... ment of myocardial infarction.

@nl

prefLabel

Autoantibodies against aldehyd ...... ment of myocardial infarction.

@en

Autoantibodies against aldehyd ...... ment of myocardial infarction.

@nl

P1476

Autoantibodies against aldehyd ...... pment of myocardial infarction

@en

P2093

E Bengtsson

http://www.w3.org/2001/XMLSchema#string

G N Fredrikson

http://www.w3.org/2001/XMLSchema#string

P Dunér

http://www.w3.org/2001/XMLSchema#string

P2860

Lysosomal enzymes are released from cultured human macrophages, hydrolyze LDL in vitro, and are present extracellularly in human atherosclerotic lesions

Recent insights into the cellular biology of atherosclerosis

Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease.

B cells and humoral immunity in atherosclerosis

Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis.

The importance of lipid-derived malondialdehyde in diabetes mellitus.

The immune system in atherosclerosis.

A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice.

Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study.

Low Levels of IgM Antibodies against an Advanced Glycation Endproduct-Modified Apolipoprotein B100 Peptide Predict Cardiovascular Events in Nondiabetic Subjects.

P304

496-507

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JOIM.12659

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

282

http://www.w3.org/2001/XMLSchema#string

P50

Jan Nilsson

J Vallejo

P577

2017-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28944562

http://www.w3.org/2001/XMLSchema#string

P921

autoantibody